Takeda seeks 'big data' analytics for rare disease drug discovery
This article was originally published in Scrip
Executive Summary
Takeda Development Center Americas – a unit of Takeda Pharmaceutical – is teaming up with big data solutions company BioXcel to research and repurpose assets for use in rare and ultra-rare disease indications.
You may also be interested in...
Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.